Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

NEUROSENSE THERAPEUTICS LTD (NRSN)

13 + Investors. Track Smart Money conviction in NRSN. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
40%

Smart Money Signals — NRSN

Based on 13 hedge funds · latest filing: 2026 Q1 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
📊

High ownership — 81% of 3.0Y peak

81% of all-time peak
13 funds currently hold this stock — 81% of the 3.0-year high of 16 funds (reached 2025 Q2). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +18% more funds vs a year ago

fund count last 6Q
+2 new funds entered over the past year (+18% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 40% buying

4 buying6 selling
Last quarter: 6 funds reduced or exited vs 4 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~3 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 8 → 1 → 5 → 3. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 31% long-term, 38% new

31% conviction (2yr+) 31% medium 38% new
Of the 13 current holders: 4 (31%) held >2 years, 4 held 1–2 years, and 5 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
➡️

Steady discovery — ~3 new funds/quarter

2 → 8 → 1 → 5 → 3 new funds/Q
New funds entering each quarter: 8 → 1 → 5 → 3. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 38% veterans, 46% new entrants

38% veterans 15% 1-2yr 46% new
Of 13 current holders: 5 (38%) held 2+ years, 2 held 1–2 years, 6 (46%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

Strong quality — 34% AUM from major funds

34% from top-100 AUM funds
6 of 13 holders rank in the top 100 by AUM, accounting for 34% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — NRSN

In 2026 Q1, 4 hedge funds were net buyers of NRSN (3 opened a new position, 1 added to an existing one), while 6 reduced or exited (3 trimmed, 3 sold completely) — a 40% buyer ratio, indicating roughly balanced activity. 34% of total institutional value in NRSN is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 13.

Hedge Fund Ownership: NRSN

How many hedge funds hold NRSN — quarterly history vs. share price
Quarterly hedge fund ownership of NRSN vs. share price

Market Analysis: NRSN

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: NRSN

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy NEUROSENSE THERAPEUTICS LTD (NRSN) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much NRSN has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 64d ago
NRSN
+3.9%
XLV
+0.0%

NRSN outperformed XLV by +3.9% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 19d ago
NRSN
-5.1%
XLV
+0.0%

Since the filing became public, NRSN outperformed XLV by -5.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

0 top-rated funds 0 high-conviction
Consensus
0.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: NRSN
13 + Investors

Track Smart Money conviction in NRSN. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 13 13 -
13F Shares 380K 346K 9.7%
Total Value $287K $266K 7.69%
New Positions 3 5 -2
Increased Positions 1 3 -2
Closed Positions 3 2 +1
Reduced Positions 3 1 +2
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: NRSN

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

13 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NRSN. Verified SEC 13F-HR filings.

QUARTER:
Top 12 institutional holders of NRSN — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Yorkville Advisors Global, LP 0.04% 78,000 $59K
2 Independent Advisor Alliance 0.00% 50,000 $38K
3 MEITAV INVESTMENT HOUSE LTD 0.00% 40,000 $30K
4 Pathstone Holdings, LLC 0.00% 16,528 $12K
5 TWO SIGMA INVESTMENTS, LP 0.00% 44,445 $34K
6 COMMONWEALTH EQUITY SERVICES, LLC 0.00% 22,775 $17K
7 PNC FINANCIAL SERVICES GROUP, INC. 0.00% 21,150 $16K
8 Creative Planning 0.00% 11,911 $9K
9 UBS Group AG 0.00% 49,096 $37K
10 SBI Securities Co., Ltd. 0.00% 265
11 JANE STREET GROUP, LLC 0.00% 28,670 $22K
12 JONES FINANCIAL COMPANIES LLLP 0.00% 1,000
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — NEUROSENSE THERAPEUTICS LTD (NRSN)

What does the Smart Money Trend signal show for NRSN?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for NRSN?

More sellers than buyers — 40% buying: Last quarter: 6 funds reduced or exited vs 4 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for NRSN holders?

Strong quality — 34% AUM from major funds: 6 of 13 holders rank in the top 100 by AUM, accounting for 34% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NRSN?

Mixed — 31% long-term, 38% new: Of the 13 current holders: 4 (31%) held >2 years, 4 held 1–2 years, and 5 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy NEUROSENSE THERAPEUTICS LTD (NRSN) following the 2026 Q1 hedge fund 13F filings?

As of today, NRSN has moved -5.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of -5.1%. Since the quarter end (March 31, 2026), NRSN has gained +3.9% vs +0.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →